Business
Aurora Strengthens Leadership Position in Germany with EU-GMP Certification at Preeminent Local Cannabis Production Facility
Aurora Strengthens Leadership Position in Germany with EU-GMP Certification at Preeminent...
About this update from Aurora Cannabis Inc.
[{"type":"text","content":"\n \n \n \n Aurora Strengthens Leadership Position in Germany with EU-GMP Certification at Preeminent Local Cannabis Production Facility\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n State-of-the-art facility readying first delivery of medical grade cannabis for German patients\n \n \n \n \n EDMONTON, AB\n \n \n ,\n \n \n May 18, 2022\n \n \n /CNW/ - Aurora Cannabis Inc. (the \"\n \n Company\n \n \" or \"\n \n Aurora\n \n \") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the company has received EU-GMP certification for its state-of-the-art medical cannabis production facility in\n \n Germany\n \n . As a leading manufacturer of medical cannabis worldwide, achieving EU-GMP certification of the company's first German manufacturing site marks a significant milestone in the fulfillment of an awarded tender by the German Federal Institute for Drugs and Medical Devices (BfArM). Aurora is the distinct market leader in the German flower segment and will now leverage receiving the world's highest quality standard to produce and distribute premium medical cannabis in\n \n Germany\n \n .\n \n \n \n \n \n \n \n \n \n The new state-of-the-art production facility in Leuna, Saxony-Anhalt,\n \n Germany\n \n adds to the company's pan-European network of EU-GMP facilities supplying premium, high-quality cannabis flower and extracts for medical use by patients across existing and expanding markets.\n \n Germany's\n \n medical cannabis market currently serves approximately 100,000 patients, representing only 0.1% of the population. In mature medical cannabis markets like\n \n Canada\n \n , market penetration is upwards of 1%, therefore the German market has significant potential for growth.\n \n \n \"With the EU-GMP certification of our first German site, we once again demonstrate Aurora's excellence and leadership in establishing the necessary infrastructure to compete in the global cannabis market,\" said\n \n Miguel Martin\n \n , CEO of Aurora ...